Background: Active surveillance (AS) is an option for men with low-risk prostate cancer (PCa). PTEN and ERG have been considered as potential biomarkers of PCa progression and survival. Objective: To study the role of ERG and PTEN status in the Prostate Cancer Research International: Active Surveillance (PRIAS) trial diagnostic biopsies (DBxs) in predicting surveillance discontinuation and adverse surgical findings in subsequent radical prostatectomy (RP). Design, setting, and participants: A total of 231 patients were recruited to the PRIAS between 2007 and 2013 in Helsinki. DBx tissue for immunohistochemistry (IHC) was available from 190 patients. Tissue microarrays (TMAs) were constructed from 57 specimens of subsequent RPs. DBxs containing grade group (GG) 1 PCa and RP TMA sections were stained with ERG and PTEN antibodies, and scored as either negative or positive. Outcome measurements and statistical analyses: Outcomes were followed up by biopsy GG upgrade (GG ! 2) and protocol-based treatment change, as well as adverse findings in RP (GG ! 3 or pathological stage ! 3). Clinical variables and biomarker status in DBx were correlated in Cox regression analysis and cumulative survival in Kaplan-Meier analysis, and finally, Gray's competing risk analysis was performed and nonprotocol-based discontinuation was considered as a competing event. Results and limitations: In both uni-and multivariate Cox regression analyses, only the number of positive cores in the DBx, the number of rebiopsy sessions, and PTEN status at diagnosis were significantly associated with rebiopsy GG upgrade, treatment change, and adverse histopathology in RP. In Kaplan-Meier analysis, PTEN loss was associated with a shorter time to GG upgrade and treatment change. Patients with PTEN loss had a higher probability for protocol-based discontinuation but not for competing risk factors compared with patients with intact PTEN. Biopsy ERG status was concordant with RP TMA ERG status, while PTEN was not. Limitations include a retrospective analysis of prospective cohort data. Conclusions: PTEN status at diagnosis is a potential biomarker for identifying patients with PCa on AS with a high risk for progression or adverse findings on subsequent RP. Patient summary: A simple diagnostic biopsy-based analysis of PTEN status may help identify patients with high risk for prostate cancer progression.
1.
Introduction Active surveillance (AS) has emerged as an option to avoid or postpone the adverse effects of curative treatments in men with low-risk prostate cancer (PCa). After 5-yr followup, half of the patients are directed to other treatments, still a substantial number of them showing favorable findings in subsequent radical prostatectomy (RP) [1] . Only a few factors available at diagnosis, namely, prostate-specific antigen (PSA) density (PSAD) and the number of positive cores in diagnostic biopsies (DBxs), are known to be associated with progression and treatment change during surveillance [2] . There is an unmet need for better prognostic and predictive tools for patients considered for AS. Biomarkers, tissue genomics, and magnetic resonance imaging (MRI)based tools have been proposed, but none have yet been widely accepted for clinical practice.
ERG oncogene is commonly fused with an androgenregulated transcription factor, TMPRSS2, in PCa. ERG: TMPRSS2 fusions are present in 36-78% of primary PCas [3] [4] [5] and have been suggested to occur early in carcinogenesis. Recently, it was postulated that ERG protein expression in DBxs would predict progression during AS [6] .
PTEN is a tumor-suppressor gene that is inactivated by genetic alterations in 18-42% of PCa [7] [8] [9] [10] . Loss of PTEN activates the phosphoinositide 3-kinase pathway and causes the activation of mammalian target of rapamycin pathway, which leads to increased cell growth and proliferation. PTEN loss has also been shown to be associated with poor prognostic parameters, such as adverse pathological features(high Gleason score [GS] and advanced pathological stage [pT]) [11, 12] , recurrence, shortened disease-specific survival (DSS) after surgery [11, 13] , shortened metastasisfree survival (MFS) after RP [12] , and DSS in castrationresistant PCa [7, 14] . A recent study of matched archival biopsy and surgical specimens showed that PTEN loss in GS 3 + 4 biopsies predicted locally advanced disease in RP [15] .
IHC has been shown to be an accurate and cost-effective method to detect both ERG fusion protein and PTEN expression, and PTEN IHC may detect nondeletion inactivation of the gene, especially in the second allele, and thus may be superior to fluorescence in situ hybridization [12, 16, 17] .
In this study, we evaluated both ERG and PTEN IHC status in DBx of patients with low-risk PCa on AS according to the Prostate Cancer Research International: Active Surveillance (PRIAS) protocol, to test whether these biomarkers would predict later progression at the time of diagnosis and possible adverse findings in subsequent RP.
2.
Patients and methods 
RP TMA construction
All the separate cancer foci in the RP specimen were marked on the diagnostic hematoxylin and eosin glass slides and subsequently punched into recipient TMA blocks with a 1.0-mmdiameter core device. Altogether, four TMA blocks were constructed, constituting of a minimum of three cores per cancer focus and one adjacent benign core per each RP specimen.
Immunohistochemistry
Altogether, two 4 mm consecutive sections were cut from FFPE 
Scoring of protein expression
Two independent investigators (U.L. and T.M.) evaluated the expression of ERG and PTEN in biopsy sections and RP TMA cores. Internal staining controls were endothelium for ERG and benign epithelium for PTEN.
Nuclear ERG expression was considered negative or positive (>90% of nuclei stained positive for ERG antibody) and cytoplasmic PTEN expression as either negative or positive, similarly to previous studies [11] [12] [13] . PTEN was considered lost in cancer if the staining intensity was markedly reduced compared with benign glands (internal positive control).
Statistical analysis
Progression was defined as discontinuation due to changes in protocol 3.
Results
Demographics of the entire AS patient cohort with detailed information on clinical variables and distribution of PTEN and ERG expression in DBx are shown in Table 1 and Supplementary Table S1 in online version at DOI: 10. 1016/j.euf.2017.03.004, respectively. The median followup time for the entire cohort was 46.2 mo (0.7-107.5 mo). During surveillance, 106 (52.2%) patients enrolled to AS discontinued, 72 (67.9%) due to PRIAS protocol-based reasons and 34 (32.1%) for other reasons. Nonprotocolbased reasons for discontinuation were RP/radiotherapy without progression (four patients), MRI findings solely (four patients), death by other causes (five patients), and watchful waiting (21 patients).
Of the patients who underwent protocol-based discontinuation, 34 (47.2%) discontinued due to having three or more positive cores, 35 (48.6%) due to GG upgrade, and 20 (27.8%) due to PSA-based reasons (PSA-DT <3 yr). Sixteen (22.2%) patients had more than one protocol-based reason for discontinuation. All the patients who discontinued the PRIAS due to protocol-based reasons underwent treatment with curative intention, 59 (81.9%) underwent RP, and the remaining 13 (18.1%) underwent radiotherapy.
The median percentage of cancer in DBx was 1 (0.06- 14) and not significantly different between the study groups. The median diagnostic PSA was not significantly different between the patients with PTEN loss and those with intact PTEN (Table 1) , neither was there a difference between the ERG-positive and ERG-negative patients ( Supplementary  Table S1 in online version at DOI: 10.1016/j.euf.2017.03. 004). We had complete matching of ERG DBx data for 44 patients and PTEN DBx data for 46 patients undergoing subsequent RP. ERG expression was concordant in DBx and RP, while PTEN expression was not ( Table 2) . In Kaplan-Meier survival analyses, PTEN loss indicated significantly shorter time for all study outcome events during follow-up as compared with intact PTEN (Fig. 1) . ERG protein expression status did not delineate differences in the event-free survival during the follow-up, although there was a trend that positive ERG expression in DBx leads to worse cumulative survival after several years of surveillance ( Fig. 1) . When the PTEN-negative biopsies were stratified according to ERG status, the ERG-positive patients with PTEN loss had the shortest event-free survival compared with the ERG-negative patients with PTEN loss or patients with intact PTEN ( Supplementary Fig. S1 in online version at DOI: 10.1016/j.euf.2017.03.004). In competing risk analysis, PTEN status was significantly associated with an increased probability of protocol-based treatment change (p = 0.029) but was not associated with nonprotocol-based treatment change (Fig. 2) .
In Cox regression analyses, the number of pre-DBx sessions was not associated with any of the outcomes in uni-or multivariable analysis (data not shown). PSAD was significantly associated only with treatment change in univariate analysis. The number of positive biopsy cores in DBx was significantly associated with all the outcomes. Hazard ratio (HR) for two positive cores versus one positive core only ranged from 1.83 to 3.02 in multivariable regression analyses (Table 3 ). If the patient underwent more biopsy sessions during the follow-up, it is less likely that he/she would harbor adverse findings in RP, have higher-grade cancer in subsequent biopsies, or undergo treatment change based on any protocol-based reasons. If the patient was not found with significant PCa at the first rebiopsy, he/she had considerably decreased the risk for treatment change, GG upgrade, or adverse RP findings in the following biopsies (HR 0.07-0.18, Table 3 ). The strongest predictor of the study outcomes was, however, PTEN protein expression. If a patient would have PTEN loss, he/she would harbor 2.31-5.29 times higher risk for disease progression or adverse RP findings (Table 3 ).
Discussion
GG1 PCa is generally considered clinically insignificant and may not need radical treatment with a risk for side effects without any shown benefit in reducing mortality [18, 19] . After RP, the oncological outcome is excellent, but men on AS may have better quality of life and AS seems to be more cost effective [20] [21] [22] . Biopsies hold uncertainties such as sampling error and subjectivity of grading, and thus, biomarkers of aggressive or nonindolent behavior regardless of GG are needed. Here, we showed that PTEN loss in DBxs in men with PCa on AS predicts worse outcome, that is, shorter duration of AS and worse findings in subsequent RP.
One earlier study has shown the association of biopsy PTEN protein loss to upgrading in RP specimen [23] . A recent study in GG2 biopsies showed that PTEN loss correlates with cancer extent in biopsies as well as GG upgrade, stage increase, and nonorgan-confined disease in RP [15] . These results together with our results support the use of PTEN IHC in delineating elevated risk in clinically and histologically low-risk PCa. The distribution of PTEN and ERG expression was concordant with our previous findings in large RP cohorts [13] , and PTEN loss occurs in 29/190 (15.3%) patients in the DBx cohort, whereas ERG was positive in 74 (38.9%) of the DBxs. It is important to notice that PTEN expression in DBx was prognostic despite PTEN expression not being concordant between DBx and RP lesions. This not only reflects the focal heterogeneity of PCa, but also underlines the strength of DBx PTEN IHC as an indicator of disease progression and adverse features. In our study, PTEN-negative biopsies were unilateral in 89.3% of cases, and 73.9% of patients had only one positive biopsy, suggesting a good correlation with sampling the relevant focus related to cancer progression. Our results strongly suggest that PTEN status needs to be considered as an additional tool for patient selection into AS protocol or tailored follow-up, in order to avoid the risk of undue treatment delays and negative consequences of unnecessary repeat biopsies: septic infections and patient discomfort. Contrary to PTEN, ERG expression was concordant in DBx and RP specimen. This confers that ERG:TMPRSS2 fusion is an early phenomenon during PCa development and is a more common event than PTEN loss in low-risk PCa. A considerable number of ERG-positive biopsies were PTEN negative (76.7%), which suggests that PTEN loss is a subsequent event to ERG fusion already in low-grade PCa.
PTEN deletions have been shown to correlate with early PSA recurrence in both ERG-positive and ERG-negative PCa [8] . In two large patient cohorts, PTEN loss combined with negative ERG IHC was significantly associated with shorter DSS as compared with PTEN loss in ERG-positive PCa after RP [11, 13] . We can postulate that the current finding that DBx ERG+/PTEN-patients have shorter survival than ERGÀ/ PTENpatients most probably reflects the early progression propensities in the androgen-sensitive, low-grade/low-risk PCa. The opposite is most probably true for higher-grade and higher-stage tumors, especially after androgen deprivation therapies.
We found no differences in risk or time to outcome events in Cox regression and Kaplan-Meier analyses when stratifying patients by DBx ERG status, which is in contrast with the results of Berg et al [6] . We were also able to analyze ERG status in matching RP specimens for patients who underwent RP, and found that ERG status in DBx and RP was significantly concordant, in line with the follow-up study by Berg et al [24] . However, the cohort utilized by Berg et al [6] featured a subset (20%) of patients whose clinicopathological features exceeded the protocol limits of the PRIAS (ie, DBx GS = 3 + 4, PSA >10 ng/ml, and/or >3 positive cores), whereas our cohort was enrolled strictly according to the PRIAS criteria. Definition of progression also varied. Besides histological upgrade, Berg et al [6] used more than three positive cores or bilateral positive cores, and PSA-DT <3 yr as criteria for progression. It is generally agreed that Gleason pattern 3 is a very low-risk finding, whereas Gleason pattern 4 poses a clearly increased risk for aggressive biological behavior. Therefore, we also had Gleason pattern 4 or 5 in the repeat biopsies (GG upgrade) as an independent criterion for progression. Nevertheless, these conflicting results indicate that the use of ERG status in the stratification of low-risk AS candidate PCa patients is unclear, and further studies in other larger prospective AS cohorts are needed. Our results do not support the independent role of ERG protein expression in predicting disease progression in low-risk PCa.
In contrast to ERG, the prognostic difference of PTEN expression in early PCa shown here also seems to translate to clinically relevant end points in the later stages of the disease, as emphasized by shortened DSS and MFS after surgery [11, 13] , and shorter DSS in castration-resistant PCa [7, 14] . This further supports the validity of our findings and the role of PTEN in prostate carcinogenesis.
Our study is not without limitations, the most important ones being its retrospective nature and limited sample size. We also did not have a comparative analysis of biomarker expression in DBx and consecutive biopsies, especially those with GG upgrade. Further, a spatial and temporal analysis of ERG and PTEN expression, compared with MRI-guided biopsies, would yield even more relevant information on the heterogeneity of these markers.
Conclusions
In conclusion, PTEN loss in biopsies at the time of diagnosis is a strong indicator of disease progression during AS of low-risk PCa. PTEN IHC status analysis together with the number of positive biopsies for cancer is recommended. The cumulative evidence of PTEN loss being a strong predictor of impaired survival and therapy resistance throughout the PCa continuum warrants careful consideration for earlier radical treatment, and perhaps consideration for tailored follow-up or therapies for PTEN-negative patients.
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